Histogenics inks deal to develop Neocart for the Japanese market

Histogenics (NSDQ:HSGX) has inked a deal with Medinet to develop and commercialize its Neocart implant for the Japanese market.

The Waltham, Mass.-based company’s Neocart implant is designed to repair knee cartilage damage. The product is made using a patient’s own cells, harvested from the surface of the patient’s femur.

Get the full story at our sister site, Drug Delivery Business News.

The post Histogenics inks deal to develop Neocart for the Japanese market appeared first on MassDevice.

from MassDevice http://ift.tt/2pexnVG